The low-EXOSC9 target signature, indicating high EXOSC9 activity, was significantly correlated with poor prognosis in adrenocortical carcinoma, lung adenocarcinoma, and pancreatic adenocarcinoma, among various cancers from the TCGA datasets (Fig. 7g–i). Here, EXOSC9 is linked to adrenal cortex carcinoma.